The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Ilika full-year loss widens on admin costs; says projects progressing

Thu, 13th Jul 2023 09:52

(Alliance News) - Ilika PLC on Thursday said its full-year pretax loss widened but noted that it is making progress with its Stereax and Goliath programmes.

The Romsey, England-based solid-state battery technology company said pretax loss for the year ended April 30 was GBP8.9 million, widening from GBP8.1 million the year prior. The firm noted that administrative expenses rose to GBP9.0 million from GBP8.0 million a year ago.

More positively, Ilika reported revenue of GBP33,848, up 9.6% from GBP30,878 a year ago.

The firm did not declare a dividend, unchanged from a year ago.

Ilika noted that during the year it despatched the first samples of its Stereax M50 batteries, noting that it is now focusing on completing its contract with Cirtec. It also said it will continue with its Goliath programme, which is making "continued technical progress". The firm expects to deliver data demonstrating lithium-ion energy density equivalence by the end of 2023.

Chair Keith Jackson said: "Regarding Stereax, we have built on the process qualification foundations laid in 2022 by delivering the first batches of Stereax batteries to customers in April 2023. This is a significant milestone for the team, which demonstrates our focus on product commercialisation.

"There is a tremendous amount of innovation taking place in the medical device sector, focused on improving treatments for chronic diseases and Stereax is strongly positioned to add significant value to this effort."

"We are delighted to have been awarded a significant grant to support our collaborations and the planned development work for our Goliath programme... This is an exciting time for the Goliath programme as we push towards the next phase of partner evaluation in 2024, and our ultimate goal of large-scale deployment through licensing," Jackson added.

Ilika shares fell 6.8% to 33.09 pence each on Thursday morning in London.

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
26 Apr 2024 20:02

TRADING UPDATES: Facilities by ADF profit hit by Hollywood strikes

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

24 Apr 2024 09:02

LONDON BROKER RATINGS: Investec cuts Hipgnosis Songs Fund to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

23 Apr 2024 12:14

IN BRIEF: Ilika trades in line with annual market expectations

Ilika PLC - Romsey, England-based solid-state battery technology company - Trade in the year ending April 30 has been in line with current market expe...

23 Jan 2024 14:15

Ilika interim loss narrows as turnover through UK grants surges

(Alliance News) - Ilika PLC on Tuesday reported a significantly higher turnover via UK grants resulting in a narrowed interim loss as it looked into t...

16 Jan 2024 15:28

UK earnings, trading statements calendar - next 7 days

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.